Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000904 · ClinicalTrials.gov registry record · Phase 1
Safety and Effectiveness of Anti-HIV Vaccines in HIV-Negative Adults
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
NCT00000904: Completed Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00000904 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 100 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000904, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to find out whether three different anti-HIV vaccines are safe and whether they help prevent HIV infection. These vaccines are called vCP205, vCP1433, and vCP1452. Some patients also receive another anti-HIV vaccine, gp160. The vaccines are made up of small pieces of HIV, which help the body learn to recognize and destroy HIV. You cannot get HIV from these vaccines. There are two different ways a vaccine can protect the body from infection. First, a vaccine may help the immune system make antibodies, which are proteins that recognize invading viruses or bacteria. Second, a vaccine may help the body make immune cells that destroy infected cells. The second type of vaccine is more powerful against HIV. In this study, doctors will see whether vCP205, vCP1433, vCP1452, and gp160 are good vaccines by seeing whether they help the body make immune cells.
Interventions
- BIOLOGICAL ALVAC(2)120(B,MN)GNP (vCP1452)
- BIOLOGICAL ALVAC-HIV MN120TMG (vCP205)
- BIOLOGICAL ALVAC-RG Rabies Glycoprotein (vCP65)
- BIOLOGICAL gp160 MN/LAI-2
- BIOLOGICAL ALVAC(1)120(B,MN)GNP (vCP1433)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Est. Completion | 1999-08 |
| Phase | Phase 1 |
What the finished NCT00000904 record still lists
NCT00000904 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% higher).
The record links to 0 conditions, and to 5 interventions - of which ALVAC(2)120(B,MN)GNP (vCP1452) is the first listed.
NCT00000904 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00000904 about?
NCT00000904 is a clinical study titled "Safety and Effectiveness of Anti-HIV Vaccines in HIV-Negative Adults". The purpose of this study is to find out whether three different anti-HIV vaccines are safe and whether they help prevent HIV infection. These vaccines are called vCP205, vCP1433, and vCP1452. Some patients also receive another anti-HIV vaccine, gp160. The vaccines are made up of small pieces of HIV...
What is the current status of trial NCT00000904?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 100 participants. Estimated completion is 1999-08.
What interventions are being tested in trial NCT00000904?
The interventions under investigation include: ALVAC(2)120(B,MN)GNP (vCP1452) (BIOLOGICAL), ALVAC-HIV MN120TMG (vCP205) (BIOLOGICAL), ALVAC-RG Rabies Glycoprotein (vCP65) (BIOLOGICAL), gp160 MN/LAI-2 (BIOLOGICAL), ALVAC(1)120(B,MN)GNP (vCP1433) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00000904?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00000904's enrollment target sits among peer trials
100 546th of 2000 higher than 1,411 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning